At Stealth BioTherapeutics, our work is personal. We believe strongly in the potential of our science to deliver new treatment solutions and improve quality of life for patients with diseases involving mitochondrial dysfunction, for which there are no FDA-approved treatments. Mutations in more than 250 different genes can lead to mitochondrial disorders.
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey with mitochondrial disease and raise awareness of the unmet need our programs seek to address.
Leber’s hereditary optic neuropathy, or LHON, is characterized by central vision loss. We estimate that approximately 10,000 individuals in the United States are diagnosed with LHON. There are no therapies approved by the FDA for the treatment of LHON.
Dry age-related macular degeneration, or dry AMD, the leading cause of blindness among older adults in the developed world, is characterized by symptoms such as distorted vision, reduction in low luminance visual acuity, reduced overall visual acuity and blurred vision. We estimate that dry AMD impacts more than 10 million individuals in the United States. There are no FDA or EMA approved treatments for the treatment of dry AMD.
We are invested in patient-focused therapeutic development and driven by a desire to help patients with unmet clinical needs.
Grants & Sponsorships
We support programs and initiatives that offer health care providers and patient communities access to educational information.
We are a high-energy, innovative company with a hard-working team striving to further our mission of patient-focused therapeutics development.